Observed Signal · Nov 17, 2026 · Funding · Source: CNBC Technology · Impact: 4/5 · Sentiment: Positive

Isomorphic Labs raises $5 billion for AI drug discovery

Executive Signal Summary

Isomorphic Labs, the AI-driven drug discovery company founded by Sir Demis Hassabis, has raised a $5 billion (€4.5 billion) Series C round. Co-led by Greenoaks and Sequoia Capital, the round also saw participation from Andreessen Horowitz, Alphabet, and existing investors including Thrive Capital, MGX, GV, CapitalG, Temasek, and the UK Sovereign AI Fund. The funding will accelerate the development of its AI drug design engine (IsoDDE), expand foundational biology models, and advance its therapeutic pipeline toward clinical trials. This investment highlights the massive capital flowing into AI-driven drug discovery, a sector that raised a record $23.2 billion in 2026. Isomorphic's round dwarfs other European AI drug discovery startups, which collectively raised approximately €148.2 million in the same period.

Polaris7 AgentPolaris7 Strategic Assessment
High Confidence

This large funding round highlights the growing intersection of AI and life sciences, which is a significant trend for the technology industry. While not directly adtech, it reflects the broader AI investment surge that impacts tech platforms and their capabilities.

MARKET SIGNALS

Track Isomorphic Labs Signals & Strategic Shifts

Polaris7 connects regulatory filings, primary sources, leadership changes, and M&A activity into structured intelligence. Set up your Polaris7 workspace to monitor relevant companies in your executive briefing.

  • Verified primary sources
  • Automated briefings
  • Instant watchlist setup

Key Takeaways & Evidence Grounding

  • Isomorphic Labs raised $5 billion (€4.5 billion) in Series C funding.
  • Round co-led by Greenoaks and Sequoia Capital, with Andreessen Horowitz and Alphabet participating.
  • Existing investors included Thrive Capital, MGX, GV, CapitalG, Temasek, and UK Sovereign AI Fund.
  • Funding will advance the AI drug design engine (IsoDDE) and support pipeline progression to clinical trials.
  • Drug discovery startups raised a record $23.2 billion in 2026; other European AI drug discovery startups raised €148.2 million.

Connected Companies & Entities

“Isomorphic Labs, an AI drug discovery startup founded by former Google DeepMind chief Demis Hassabis, has raised a $5 billion Series C round...”

“Hassabis stepped back as CEO of DeepMind, Google's AI lab, which he co-founded before the Big Tech giant acquired it in 2014.”

“OpenAI and Anthropic have also been investing in tools to develop new medicines using the technology.”

“Anthropic announced it was launching an AI drug discovery program in June.”

“participation from all existing investors: Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund”

“participation from all existing investors: Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund”

“participation from all existing investors: Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund”

“participation from all existing investors: Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund”

“participation from all existing investors: Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund”

Primary Source Grounding & Direct Attribution
Direct Origin Attribution
Primary Reporting: CNBC Technology•Published: Nov 17, 2026
Original Coverage Title: “Demis Hassabis’ AI company raises $5 billion, months after he left as Google DeepMind CEO”

Related Market Signals & Shifts

Recent verified developments and strategic activity across this market segment.

FinancialsNov 5, 2026

Isomorphic Labs seeks $5B round at $50B valuation

Isomorphic Labs, Alphabet's AI drug discovery spinout led by Demis Hassabis, is reportedly in early-stage talks to raise approximately $5 billion at a valuation of around $50 billion, according to Bloomberg. This round would follow a $2.1 billion Series B in May and a $600 million round in 2025, bringing total raised to nearly $7.7 billion within 18 months. Despite the massive funding, the company has not yet tested any drug candidate in humans; clinical trials were initially planned for end of 2025, then delayed to late 2026. Investors are valuing the platform rather than a product, a record for a pre-clinical biotech. Revenue currently comes from partnerships with Eli Lilly, Novartis, and Johnson & Johnson, with milestone-based payments potentially reaching up to $2.9 billion. Skepticism remains, as Eli Lilly's CEO Dave Ricks has questioned the effectiveness of AI in drug discovery, noting that protein structure prediction is just one part of the challenge.

Read assessment
FundingNov 10, 2026

Proximal Ventures Raises $27.5M for AI Drug Development Fund

Proximal Ventures, founded by former SignalFire investor Sahir Raoof, has raised $27.5 million for its debut venture capital fund. The fund will invest in pre-seed and seed-stage startups applying AI to drug development tools, infrastructure, and services. Proximal has already backed seven startups, including ChronicleBio, which uses AI to analyze biological and medical data for chronic disease research. The fund's backers include SignalFire, Kleiner Perkins, Bertelsmann Healthcare Investments, and individual investors like Dimension Capital co-founders. Raoof, who previously worked at Flatiron Health and Iterative Health, aims to capture pharmaceutical spending by offering AI-driven services that are faster and cheaper than traditional outsourcing. The fund will write checks between $500,000 and $1.5 million.

Read assessment
AINov 19, 2026

London AI drug discovery startup Boltz raises $110M Series A

Boltz, a London-based AI startup focused on drug discovery, has raised a $110 million Series A funding round, less than a year after emerging from stealth. The company develops AI models to predict protein-drug interactions and design new molecules, accelerating early-stage drug discovery. The round was led by Bessemer Venture Partners, with participation from existing investors including Andreessen Horowitz, Amplify Partners, Zetta Venture Partners, and Obvious Ventures, as well as new investors Greycroft, F-Prime Capital, Hummingbird, and Benchling. Nvidia had previously invested earlier this year. Boltz has announced collaborations with major pharmaceutical companies such as Pfizer, GSK, Takeda, and Bristol Myers Squibb. The funding will support further model development and investment in compute and data infrastructure.

Read assessment

WATCHLIST & BRIEFINGS

Receive future signals for Isomorphic Labs & competitors in your briefing

Stay ahead of material M&A deals, leadership changes, account wins, and product rollouts. Polaris7 connects primary filings, company newsrooms, and trade reporting directly into your executive briefing.

  • Regular primary-source checks
  • Structured Watchlist briefings
  • Preserves current context